Extensive industry knowledge

Our approach to due diligence incorporates proprietary knowledge and deep expertise in the Life Sciences and Health Care ecosystem. Our track record is built on a foundation that we have rigorously refined on over 50 due diligence for companies in Biotechnology (e.g., start-ups), Healthcare Providers and Services (e.g., telemedicine providers, nursing software providers), Pharmaceuticals (e.g. CDMOs, CMOs, CROs,) and other adjacent industries and sectors

Fact-driven approach

We draw upon targeted secondary and primary research with expert interviews and surveys. We evaluate the technical and commercial merits of businesses and gather important context and factual support for any red flags. We pressure test hypotheses with an internal network of senior advisors who specialise in the functional area, industry, and country of the company under evaluation.

Long-term perspective

We provide a synthesis of a whole range of factors, such as technology, customers, regulations, and the emergence of new markets that could impact the competitive state of a market and the performance of the target company. Given the urgent nature of the bidding process, our comprehensive experience enables us to root out risks buried in the vast quantities of data and focus on key and business-critical aspects. We leave no stone unturned to assess key risks that could impact the transaction outcome.

Tailored to client needs

The nature of investment dictates that the depth of commercial due diligence varies between acquisition, refinancing, co-investment or restructuring of an existing deal. We always consider the specific aspects of a target company, ensuring that our services align with client needs. Our flexible model allows for a range of potential due diligence support, from a simple report and targeted red-flag analysis to comprehensive due diligence encompassing various aspects of the market and business.